Meiji Yasuda Asset Management Co Ltd. reduced its stake in DaVita Inc. (NYSE:DVA - Free Report) by 57.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,472 shares of the company's stock after selling 8,890 shares during the period. Meiji Yasuda Asset Management Co Ltd.'s holdings in DaVita were worth $968,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in the stock. MML Investors Services LLC boosted its holdings in DaVita by 1.3% during the third quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock worth $869,000 after buying an additional 68 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in DaVita by 8.3% in the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock valued at $133,000 after purchasing an additional 68 shares in the last quarter. Impact Partnership Wealth LLC raised its holdings in DaVita by 3.7% in the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock worth $290,000 after purchasing an additional 70 shares during the period. Contravisory Investment Management Inc. boosted its position in shares of DaVita by 1.2% during the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company's stock worth $910,000 after purchasing an additional 73 shares in the last quarter. Finally, Nilsine Partners LLC grew its holdings in shares of DaVita by 0.8% in the 4th quarter. Nilsine Partners LLC now owns 11,160 shares of the company's stock valued at $1,669,000 after buying an additional 92 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.
DaVita Stock Performance
Shares of DVA traded up $2.96 during trading hours on Monday, hitting $153.18. The company had a trading volume of 661,294 shares, compared to its average volume of 808,295. The business has a fifty day moving average of $157.13 and a 200-day moving average of $157.52. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The firm has a market cap of $12.25 billion, a price-to-earnings ratio of 14.26, a PEG ratio of 1.07 and a beta of 0.99. DaVita Inc. has a 12 month low of $125.64 and a 12 month high of $179.60.
DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Equities analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.
Analyst Ratings Changes
Several research analysts have weighed in on the company. StockNews.com lowered DaVita from a "buy" rating to a "hold" rating in a report on Friday, March 21st. Sanford C. Bernstein set a $184.00 price objective on DaVita in a report on Friday, February 21st. Cowen reiterated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Barclays boosted their target price on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $166.33.
Check Out Our Latest Analysis on DVA
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
